Aprea Therapeutics, Inc.

Nasdaq:APRE

Pharmaceutical Preparations·DOYLESTOWN, PA

CEO

Gilad Oren

CFO

Hamill John P.

Financials

20 shown

Type	Period	Ended	Filed
10-Q	Q3 2025	9/30/25	11/12/25	→
10-Q	Q2 2025	6/30/25	8/12/25	→
10-Q	Q1 2025	3/31/25	5/14/25	→
10-K	FY 2024	12/31/24	3/25/25	→
10-Q	Q3 2024	9/30/24	11/7/24	→
10-Q	Q2 2024	6/30/24	8/12/24	→
↓

Earnings Releases (8-K)

28 shown

Filed	Period
11/12/25	Q4 FY2025	→
8/12/25	Q3 FY2025	→
5/14/25	Q2 FY2025	→
3/25/25	Q1 FY2025	→
1/13/25	Q4 FY2025	→
11/7/24	Q4 FY2024	→
↓

News (8-K)

52 shown

Filed	Type	Description
2/18/26	Other	Other Events	→
1/29/26	Agreement	Entry into a Material Definitive Agreement	→
1/23/26	Delisting	Notice of Delisting or Failure to Satisfy a Continued Listing Rule	→
1/9/26	Other	Other Events	→
12/9/25	Agreement	Entry into a Material Definitive Agreement	→
10/24/25	Other	Other Events	→
↓

Prospectuses & Registrations

33 shown

Filed	Form	Description
2/20/26	S-3	S-3	→
12/30/25	424B3	424B3	→
12/19/25	S-3	S-3	→
12/8/25	S-8	S-8	→
4/22/25	ARS	ARS	→
11/8/24	424B5	424B5	→
↓

Filing History(397 filings)

TypeDateAccessionPeriodSize

S-3

Feb 20, 2026

0001104659-26-017755S-3

—

484.1 KB

8-K

Feb 18, 2026

0001104659-26-016797FORM 8-K

Feb 18, 2026

209.8 KB

SCHEDULE 13G/A

Feb 13, 2026

0001104659-26-015324

—

10.7 KB

Feb 2, 2026

0001104659-26-009206OWNERSHIP DOCUMENT

Jan 30, 2026

10.2 KB

Feb 2, 2026

0001104659-26-009203OWNERSHIP DOCUMENT

Jan 30, 2026

8.5 KB

8-K

Jan 29, 2026

0001104659-26-007988FORM 8-K

Jan 28, 2026

6.8 MB

SCHEDULE 13G/A

Jan 28, 2026

0001493152-26-003971

—

9.1 KB

8-K

Jan 23, 2026

0001104659-26-006267FORM 8-K

Jan 23, 2026

187.0 KB

8-K

Jan 9, 2026

0001104659-26-0024908-K

Jan 9, 2026

4.7 MB

424B3

Dec 30, 2025

0001104659-25-124943424B3

—

228.8 KB

EFFECT

Dec 29, 2025

9999999995-25-003942

—

1.7 KB

Dec 29, 2025

0001781983-25-000003

—

14.0 KB

S-3

Dec 19, 2025

0001104659-25-123130S-3

—

490.9 KB

Dec 11, 2025

0001104659-25-120156OWNERSHIP DOCUMENT

Dec 10, 2025

9.5 KB

Dec 11, 2025

0001104659-25-120155OWNERSHIP DOCUMENT

Dec 10, 2025

8.5 KB

Dec 11, 2025

0001104659-25-120152OWNERSHIP DOCUMENT

Dec 10, 2025

11.6 KB

8-K

Dec 9, 2025

0001104659-25-119680FORM 8-K

Dec 8, 2025

1.1 MB

S-8

Dec 8, 2025

0001104659-25-119074FORM S-8

—

180.7 KB

SCHEDULE 13G

Nov 17, 2025

0000935836-25-000708

—

6.4 KB

10-Q

Nov 12, 2025

0001104659-25-10986710-Q

Sep 30, 2025

4.0 MB

8-K

Nov 12, 2025

0001104659-25-1098608-K

Nov 12, 2025

4.1 MB

SCHEDULE 13G/A

Nov 12, 2025

0001214659-25-016261

—

9.3 KB

8-K

Oct 24, 2025

0001104659-25-1020048-K

Oct 24, 2025

198.4 KB

8-K

Oct 15, 2025

0001104659-25-0995348-K

Oct 15, 2025

4.1 MB

8-K

Sep 8, 2025

0001558370-25-0119098-K

Sep 8, 2025

4.0 MB

25 filings shown

Filed	Form	Description
4/22/25	DEFA14A	DEFA14A	→
4/22/25	DEF 14A	DEF 14A	→
4/25/24	DEFA14A	DEFA14A	→
4/25/24	DEF 14A	DEF 14A	→
7/11/23	DEF 14A	DEF 14A	→
10/26/22	DEF 14A	DEF 14A	→
↓

Aprea Therapeutics, Inc.

Financials

Earnings Releases (8-K)

News (8-K)

Prospectuses & Registrations

Filing History(397 filings)

Proxies

Ownership

Other Filings

Filed	Form	Description
2/2/26	4	OWNERSHIP DOCUMENT	→
2/2/26	4	OWNERSHIP DOCUMENT	→
12/11/25	4	OWNERSHIP DOCUMENT	→
12/11/25	4	OWNERSHIP DOCUMENT	→
12/11/25	4	OWNERSHIP DOCUMENT	→
6/9/25	4	OWNERSHIP DOCUMENT	→
↓

Filed	Form	Description
2/13/26	SCHEDULE 13G/A	SCHEDULE 13G/A	→
1/28/26	SCHEDULE 13G/A	SCHEDULE 13G/A	→
12/29/25	EFFECT	EFFECT	→
12/29/25	D	D	→
11/17/25	SCHEDULE 13G	SCHEDULE 13G	→
11/12/25	SCHEDULE 13G/A	SCHEDULE 13G/A	→
↓